A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474.
A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474.
复制标题
DOI：
10.1038/bjc.1971.33
复制
发表时间：
1971-06
影响因子：
8.8
通讯作者：
Todd ID
中科院分区：
文献类型：
--
作者：
Cole MP;Jones CT;Todd ID
介绍了抗雌激素药物IC146474治疗晚期或复发乳腺癌的介绍性临床试验。46名患者接受了治疗，其中10名患者表现出良好的反应。这与雌激素和雄激素的作用是相同的。这种药的特别优点是副作用发生率低。
An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described. Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens. The particular advantage of this drug is the low incidence of troublesome side effects.